Publications

Immuno-oncology technology

IOTECH in times of COVID-19.

01-06-2020

Cancers

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy.

07-05-2020

Clinical cancer research : an official journal of the American Association for Cancer Research

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

01-05-2020

Pigment cell & melanoma research

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.

01-05-2020

Cancers

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs.

18-04-2020

Nature medicine

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

01-04-2020

European urology oncology

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.

01-04-2020

Journal of geriatric oncology

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials.

01-04-2020

Oncoimmunology

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination.

22-03-2020

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.

01-01-2020

Cancers

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

04-12-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

01-12-2019

European journal of cancer (Oxford, England : 1990)

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.

01-12-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Gender medicine and oncology: report and consensus of an ESMO workshop.

01-12-2019

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.

01-11-2019

European journal of cancer (Oxford, England : 1990)

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

01-11-2019

Oncoimmunology

Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile.

28-10-2019

The New England journal of medicine

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

17-10-2019

Immuno-oncology technology

The promise of IO and IOTECH.

01-10-2019

European urology

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

01-10-2019

Immuno-oncology technology

Getting visible with exciting IO tech!

01-09-2019

European journal of cancer (Oxford, England : 1990)

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

01-09-2019

ESMO open

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

20-08-2019

ESMO open

Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs.

20-08-2019

The New England journal of medicine

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

15-08-2019

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology.

01-08-2019

Cancers

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

18-07-2019

Journal for immunotherapy of cancer

Transgenerational transfer of gene-modified T cells.

15-07-2019

The Lancet. Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

01-07-2019

Future oncology (London, England)

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

01-07-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

01-07-2019

ESMO open

How I treat MSI cancers with advanced disease.

25-06-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

01-06-2019

Nature medicine

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-06-2019

Insights into imaging

Cryoablation and immunotherapy: an overview of evidence on its synergy.

20-05-2019

Cancer immunology, immunotherapy : CII

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

01-05-2019

Virchows Archiv : an international journal of pathology

Adoptive cellular therapies: the current landscape.

01-04-2019

Nature medicine

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.

01-04-2019

The New England journal of medicine

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

21-03-2019

Cancer immunology, immunotherapy : CII

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

01-03-2019

Oncoimmunology

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

07-02-2019

Cell

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

07-02-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

01-02-2019

JAMA oncology

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

01-02-2019

Cancer immunology, immunotherapy : CII

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

01-02-2019

Cancer immunology research

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

01-01-2019

Journal of biotechnology

Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method.

01-01-2019

Nature medicine

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.

01-01-2019

Cancer immunology research

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.

01-01-2019

IOTECH in times of COVID-19.

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy.

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs.

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials.

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination.

Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.

Gender medicine and oncology: report and consensus of an ESMO workshop.

Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

The promise of IO and IOTECH.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

Getting visible with exciting IO tech!

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Transgenerational transfer of gene-modified T cells.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

How I treat MSI cancers with advanced disease.

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Cryoablation and immunotherapy: an overview of evidence on its synergy.

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

Adoptive cellular therapies: the current landscape.

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method.

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.

This site uses cookies